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The recognition of sessile form of bacteria with particular features, known as biofilm, has given new insights to the
understanding of pathogenesis of several chronic diseases, including Chronic Rhinosinusitis (CRS). In this article
we review the main characteristics of biofilms, describe the current methods used to demonstrate biofilms in
chronic rhinosinusitis and discuss the future directions of research in the field.
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For decades, Koch’s four postulates were the paradigm to
explain most of infectious diseases currently known. However,
several recurrent and chronic infectious diseases could not
be explained by the free-floating bacteria model of Koch’s
postulates. The discovery of a sessile conformation of bacteria
known as biofilms in the 1980’s has brought much interest to
the study of the contribution of bacterial biofilms with many
recurrent and chronic infectious diseases. A recent report by
the Center for Disease Control and Prevention estimated that
65% of all infectious diseases in humans are related to biofilms
[1]. Because of the increasing interest in biofilms over the last
decades, we review the basic concepts related to biofilm
microbiology and associated clinical implications and review
the current evidence supporting the role of biofilms in chronic
rhinosinusitis as well as future directions in research.
What are Bacterial Biofilms?
Bacteria can be found in nature in two distinct forms: free-
floating cells denominated as planktonic or sessile forms
known as biofilms. Biofilms are an adaptive phenotypic switch
of prokaryotic life that virtually can be found in all living
bacteria. Indeed, biofilms are the main mode of survival and
bacterial proliferation. Morphologically, biofilms are
characterized by a three dimensional complex of bacteria
enclosed in a self-produced extracellular matrix formed by
polysaccharides, nucleic acids, proteins and extracellular DNA
(Figure 1). Approximately 90% of the biofilm mass is water
with the remaining 10% of the mass being formed by
extracellular matrix (8.5%) and cells (1.5%) [2].
The pores and water channels integral to the biofilm
structure are the primary modes for nutrient and waste by
product exchange with the external environment and are
accomplished via both active and passive mechanisms. The
physical structure of the biofilm establishes a decreasing oxygen
and nutrient gradient from periphery to center which creates a
bacterial metabolic gradient in the same direction, with different
susceptibility to antibiotics and to innate and adaptive host
defenses [3]. These characteristics, allied to the ability of the
biofilm community to detach viable bacteria and colonize distant
niches, have given an increasing interest in biofilms in the
understanding of persistent and recurrent infectious diseases.
How are Biofilms Formed?
Based on proteomic studies of Pseudomonas aeruginosa,
five sequential and dynamic steps have been proposed to the
formation of biofilms [3]. The first step starts with a random
contact of bacteria with an inert or live surface. The initial
contact is influenced by some features of the environment,
such the presence of shearing forces or an air-liquid interface.
Under certain environmental conditions, the bacteria use a
signaling cascade to evoke phenotypic changes through the
activation of selected genes involved in biofilm formation.
This process is initiated with the production and secretion of
signaling molecules that, depending on the concentration
reached in the microenvironment, trigger the cascade
necessary for biofilm formation. This tightly regulated process
of cell-to-cell communication to initiate the biofilm phenotype
is known as quorum-sensing.
Once the cascade is initiated, the second stage is the
production of extracellular matrix that adheres the bacterial
complex to the surface. The third stage is microcolony
formation, the two dimensional clustering of bacteria. Once
the microcolonies achieve a critical mass, vertical growth is
initiated resulting in towers with intervening water channels
and increase of polymeric extracellular matrix. Tower formation,
however, is dependent of nutritional conditions of external
environment that can either influence clonal cell growth or
bacterial motility to form towers. In this step, colonizers like
fungi and other bacteria can associate itself to the biofilm
structure. In the last step, shearing forces as well as unknown
conditions can induce detachment of free living bacteria to
colonize far niches to maintain the bacterial cycle (Figure 2).
What are the Advantages to Bacteria to Form a Biofilm?
From an evolutional point of view, bacterial growth attached
to a surface brings several advantages to survival and
prokaryotic perpetuation. The attachment to a surface creates
a certain degree of stability for survival, with a possibility to
interact and cooperate as well as share genetic material with
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other cells within the biofilm community thereby greatly
enhancing the gene pool. Another advantage is that bacteria
within the biofilm are physically less susceptible to
environmental factors, such as ultra-violet radiation,
dehydration, variations of pH and osmolarity [3].
One of the most important features of biofilms is the high
resistance to antibiotics and to host immune mechanisms such
as less susceptibility to opsonization and phagocytosis [4,5].
In vitro tests have demonstrated that certain strains of bacteria
in a biofilm state can be more than 1000 times more resistant to
antibiotics compared to the minimum inhibitory concentrations
levels of their planktonic counterparts [6]. One of the
mechanisms of resistance is due to the physical barrier exerted
by the polyssacharide matrix that blocks the diffusion of the
compounds or inactivates the biocide activity of some agents.
This is mainly important for reactive agents (i.e. superoxides)
and immunoglobulins [7,8]. However, some studies have
shown that many antibiotics are able to cross the
exopolyssacaride matrix but do not have the expected
antimicrobial activity [9]. This in part can be explained by the
reduced metabolic activity found in the core of the biofilm
resulting from lower concentrations of nutrients and oxygen.
As most antibiotic act on active metabolic bacteria, like β-
lactams, they would be expected not to have the highest effect
in the core zones or “dormant” areas of the biofilm. This could
explain the persistence of biofilm even after higher doses of
appropriate antibiotic [10]. Other hypotheses to explain
antibiotic resistance is that the water channels could pump
the antibiotic out in an active manner [11].
Diseases that present with high resistance to conventional
antibiotic therapy, with intermittent periods of acute
exacerbations, difficult to identify and culture the microorganism,
are the typical paradigm of biofilm-related diseases. Because of
the long time adherence to a surface in addition to the ability to
spread viable planktonic bacteria to far sites, biofilms can fit the
pathophysiological model of several chronic and recurrent
diseases. In this way, many studies have shown the relation of
bacterial biofilms to dental plaques, urinary infections,
prostatitis, pneumonia in cystic fibrosis patients, otitis media
and, more recently, in chronic rhinosinusitis [12].
Methods of Study and Evidence of Biofilms in Rhinosinusitis
The understanding of biofilms has gained momentum as
the methods of study have evolved. Currently, the main
methods used to evaluate biofilm in rhinosinusitis are based
on imaging studies (scanning electron microscopy,
transmission electron microscopy, confocal scanning laser
microscopy) and on methods that evaluate in vitro the
formation and/or susceptibility of biofilms in 96-well plates
assays [12], such as the Calgary Biofilm assay.
Scanning Electron Microscopy (SEM) and Transmission
Electron Microscopy (TEM)
Much of the current knowledge about biofilms is due to
the advances in imaging studies, especially the SEM. The
ability to acquire images in high magnification, with structural
microscopic details, is the main advantage of SEM. TEM, in
turn, can elucidate ultra structural details of biofilms, like the
composition and the interaction of extracellular matrix with
the surface and cells in the vicinity.
However, both SEM and TEM have the disadvantage of
artifacts inherent to the processing of the samples, which
include dehydration and distortion of the surface. Another
drawback is that SEM and TEM require very small pieces to
be analyzed, which could add a sampling error bias.
The first study of biofilms in rhinosinusitis was published
by Cryer et al. [13] in 2004, which identified bacterial biofilm in
4 of 16 patients with CRS by SEM. In another study from the
same laboratory, Perloff and Palmer [14] evaluated the presence
of biofilms in silastic stents removed from the frontal sinus
recess after endoscopic sinus surgery (Figure 3). In this study,
all 6 patients presented with biofilm on these sinus stents.
Using TEM, Ferguson and Stolz [15] demonstrated the
presence of bacterial biofilms in 2 of 4 patients with CRS. Also
using SEM and TEM, Sanclement et al. [16] in 2005
demonstrated a prevalence of 80% (24/30) of biofilms in
mucosal biopsies of CRS patients. None of the 4 control
patients was found to be biofilm positive. Although potential
artifacts can arise from the fixation and dehydration inherent
to SEM processing, these authors claim that the conventional
SEM processing does not change significantly the biofilm
architecture and keep possible the recognition of biofilm on
mucosal samples.
In children, Zuliani et al. [17] compared the presence of
biofilms by SEM in adenoids in CRS versus Obstructive Sleep
Apnea. CRS samples had 94.9% of the adenoid surface
occupied by biofilm, in contrast to 1.9% in cases of obstructive
sleep apnea. In this study they concluded that biofilms in the
nasopharynx can be a reservoir for resistant bacteria and the
elimination of this resource by adenoidectomy could explain
the clinical improvement seen in these children.
Confocal Scanning Laser Microscopy (CSLM)
Another method that has gained interest in biofilm
identification is the CSLM. Although the CSLM does not
provide high imaging magnifications like SEM, its main
advantage over the other methods is the possibility to visualize
a specimen without fixation or dehydration of the sample,
thereby minimizing possible architecture alterations of the
biofilms. Another advantage is the possibility to stain bacterial
cells or fungi selectively with fluorescent markers, such the
probes used in in situ hybridization or nucleic acid markers to
distinguish viable from non-viable cells.
Utilizing 4 different markers for fluorescent in situ
hybridization (FISH), Sanderson et al. [18] demonstrated the
presence of biofilms in 14 of 18 patients with CRS, including
some samples with polymicrobial staining. However, 2 of 5
control samples showed positive staining for biofilms. Because
the biofilms found in these control samples were significantly
smaller than the CRS group, the authors suggest they might
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Figure 1. Scanning Electron Microphotograph. Pseudomonas
aeruginosa (PA0-1) biofilm obtained after 24 hours of
incubation over a polystyrene membrane. Note the bacilli
(white arrow) enclosed in an extracellular matrix (black arrow)
with water channels.
Figure 2. Biofilm formation cycle. (I) Planktonic bacteria; (II)
Random contact of free-floating bacteria on a surface; (III)
Formation of bacterial anchoring to the surface (IV); Growth
of microcolonies; (V) Biofilm maturation and detachment of
planktonic bacteria.
be only colonizers. Psaltis et al. [19], using CSLM associated
with the Baclight LIVE/DEAD® kit staining, demonstrated that
17 of 38 patients (44.7%) with CRS were biofilm positive and
none of the 9 control patients showed evidence for biofilm.
Modified Calgary Biofilm Assay
The modified Calgary Biofilm Assay is a 96-well plate test
evaluates the ability of bacteria to form biofilm on round pegs
positioned over the plate. Originally describe to evaluate antibiotic
Figure 3. Scanning Electron Microphotograph. Silastic stent
removed from the frontal sinus recess after the 7th post
operative day, with biofilms on the surface.
susceptibility and to compare the resistance to their planktonic
counterparts [6], the modification described by Stepanovic et al.
[20] consist in a semi-quantitative analysis of the amount of crystal
violet absorbed by the biofilms grown on the pegs. The advantage
of this method is the easy applicability and low cost. However, as
an in vitro test, the biofilm formation evaluated on the pegs may
not reflect the same behavior in vivo.
Besides the evidences in sinonasal mucosa, a study using
the Calgary Biofilm Assay demonstrated a prevalence of 28.6%
of bacterial biofilm formers in swabs collected from patients
with CRS [21]. Using a similar method, Bendouah et al. [22]
demonstrated that when Staphylococcus aureus or
Pseudomonas aeruginosa recovered from CRS patients are
able to form biofilm, they are associated with an unfavorable
post operative evolution based on nasal endoscopy and on
quality of life scores. In the same way, Psaltis et al. [23]
demonstrated that the presence of biofilms on sinus mucosa
of CRS patients were associated with worse symptoms and
mucosal inflammation in the post-operative follow up.
Future Perspectives in Research and Clinical Applications
Although there is much evidence suggesting a link
between biofilms and CRS in humans, there is little knowledge
about its real contribution in the pathophysiology of CRS.
There are no studies that clearly demonstrate which factors
determine the persistence and growth of biofilm on the
sinonasal mucosa of the host.
Due to the difficulty of studying biofilms on a viable tissue
culture or even in animals few investigations have been able to
successfully delve into evaluating the interactions between
host and biofilms. Starner et al. [24] using broncho-epithelial
human cells, demonstrated that H. influenza biofilms grown on
Bacterial Biofilms in Chronic Rhinosinusitis
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these cell cultures evoked an inflammatory response with an
increase of NF-kB, IL-8, TNF-α, and MIP-3α (macrophage
inflammatory protein). Therefore, many studies are still required
to understand the different mechanisms of interaction between
host and biofilms, what drives the formation of biofilms in these
patients, and development of an understanding of the humoral
and cellular defense responses involved.
To better understand the behavior of biofilms in sinonasal
mucosa, few studies using animal models have been published.
Perloff and Palmer [25], demonstrated that maxillary sinusitis
induced by P. aeruginosa in rabbits in different endpoints, until
the 20th day of infection, were associated with biofilm formation
on sinus mucosa. Recently, Ha et al. [26] using a sheep model for
sinusitis demonstrated that sinus ostium occlusion substantially
promoted biofilm formation in the inoculated sinus.
Broadly, therapeutic intervention can be divided into: (1)
possible manners to inhibit biofilm formation and (2) methods
to eradicate biofilm already formed. Chiu et al. [27,28] and
Antunes et al. [29] have developed an animal biofilm sinusitis
model with an indwelling irrigation catheter for screening
antibiofilm activity of different topical agents, like antibiotics
and/or surfactants. This model may develop into the workhorse
for future topical drug development as it can be easily used to
assess the efficacy and safety of anti-biofilm agents, like anti-
quorum sensing drugs [30].
Finally, the development of more feasible methods for
biofilm detection could contribute with new perspectives and
direction of therapies in patients that present with chronic
and recurrent infectious diseases, such as CRS.
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